Life Sciences
Mexico: Government promotes reforms and amendments to health legislation to strengthen control of health products and services
In recent years, the regulatory framework in the field of health has undergone a profound transformation. Recent reforms seek to strengthen the protection of public health, regulate sensitive products and services, and expand the powers of health authorities. These measures range from banning vapers to incorporating digital health and alternative medical dispute resolution mechanisms.Mexico: The Constitution is amended to broaden the grounds for preventive imprisonment
On April 1, 2025, a decree was published reforming article 19 and adding article 40 of the Constitution, expanding the cases in which the official pre-trial detention is applicable. It includes crimes such as the use of chemical precursors, smuggling and falsification of tax receipts. The reform implies greater criminal risk for individuals and companies that operate with regulated products, even without malicious intent.China Legal Newsletter - October 2024
This newsletter highlights key recent developments in China’s laws and regulations. Specifically, it focuses on the laws and regulations related to foreign investment, market access, foreign debt administration, data economy, privacy and cybersecurity, labor and employment, life sciences and healthcare, as well as other topics.European Parliament gives support to pharmaceutical strategy for Europe
The European Parliament gave its support to the pharmaceutical strategy for Europe, by resolution on November 24, 2021. Two main driving forces behind this strategy, adopted by the European Commission on November 25, 2020, are to support industry in promoting research and to address certain market failures. The aim is to create a regulatory framework for the future.The new regulations on observational studies of medicinal products for human use reduce procedures and introduce significant new legislation
Royal Decree 957/2020 simplifies the process for conducting observational studies through a common single evaluation procedure for all studies of this type and by reducing the prior requirements. It also introduces changes in relation to the informed consent of patients participating in the study and the associated financial elements, as well as to the transparency and reporting obligations, among other matters.COVID-19: News in the medical devices industry in Europe and in Spain
Below we summarize some of the specific measures adopted in relation to medical devices by the main European and Spanish authorities. These measures are part of the set of new pieces of legislation affecting the pharmaceutical and healthcare industry as a result of the crisis caused by the impact of the COVID-19 virus, which are being analyzed by the firm.Pharmaceutical and healthcare industry: the impact of the COVID-19 measures
Some of the measures adopted in recent weeks to tackle the economic and social impact of COVID-19 have special implications for the healthcare and pharmaceutical industry. In this article we analyze the key information that companies in this field need to take into account.Garrigues collaborates with Foundation29 specialized in artificial intelligence applied to health
Foundation29 (Fundación 29 de febrero) is a non-profit organization specialised in artificial intelligence applied to health. It creates technological tools based on aggregation, treatment and protection of medical data and its use in intelligent systems that help patients, professionals and industry take decisions.